Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

umeclidinium bromide

- PMLiVE

Takeda’s dengue vaccine candidate recommended for approval by CHMP

Dengue disease causes around 390 million infections and 500,000 hospitalisations each year

- PMLiVE

Novartis bags CHMP recommendation for prostate cancer drug Pluvicto

The recommendation is for use in combination with androgen deprivation therapy

- PMLiVE

BeiGene’s Brukinsa receives CHMP recommendation for chronic lymphocytic leukaemia

CLL accounts for around one-quarter of new leukaemia cases

- PMLiVE

GSK announces positive phase 3 results of RSV vaccine candidate in older adults

RSV infections in older adults account for around 177,000 hospitalisations in the US each year

- PMLiVE

GSK’s Boostrix approved by FDA for use during pregnancy to prevent whooping cough in infants

4.2% of the cases of pertussis reported in the US in 2021 were in infants younger than six months

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

GSK awarded first-ever UNICEF contract for malaria vaccine in deal worth £170m

In 2020, nearly half a million children died from malaria in Africa alone, a rate of one child death per minute

- PMLiVE

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

Developed in collaboration with GSK, CV0501 is specifically designed to protect against the Omicron variant

- PMLiVE

GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA

40% of myelofibrosis patients are already anaemic at the time of diagnosis and nearly all patients are estimated to develop anaemia eventually

- PMLiVE

GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention

The agreement aims to expand access to HIV prevention in the developing world

- PMLiVE

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma

If approved by the EC, Opdualag would be the first LAG-3 blocking antibody combination available in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links